Equities

NRX Pharmaceuticals Inc

NRX Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.26
  • Today's Change-0.01 / -0.79%
  • Shares traded113.73k
  • 1 Year change-61.81%
  • Beta1.2480
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.

  • Revenue in USD (TTM)0.00
  • Net income in USD-24.83m
  • Incorporated2017
  • Employees2.00
  • Location
    NRX Pharmaceuticals Inc1201 ORANGE STREET, SUITE 600WILMINGTON 19801United StatesUSA
  • Phone+1 (484) 254-6134
  • Fax+1 (302) 575-1642
  • Websitehttps://www.nrxpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cardio Diagnostics Holdings Inc39.14k-8.77m12.41m7.00--3.08--317.11-0.4899-0.48990.00210.13190.0073--9.135,591.43-163.16---268.73-------22,414.13-----9.320.0295--1,696.84---79.72------
Oncotelic Therapeutics Inc70.00k-1.24m12.59m22.00--1.04--179.92-0.0031-0.00310.00020.02990.0023--3.693,181.82-5.02-25.03-11.26-48.76-----2,147.66-1,692.93---0.51670.5228-------255.12------
Protext Mobility Inc750.00-2.21m13.19m4.00------17,582.44-0.4692-0.46920.00001-0.01020.0405-------9,400.97-1,587.94----86.67-530.19-232,392.00-17,498.830.0002-1.36-----93.98-63.0927.35------
Biomx Inc0.00-26.25m13.22m58.00---------0.4575-0.45750.000.39290.00----0.00-47.79---57.76--------------0.00------7.59------
Apollomics Inc0.00-57.11m13.22m45.00--0.6337-----0.568-0.5680.000.18920.00----0.00-107.81---144.29--------------0.185------28.33------
OpGen Inc1.96m-22.39m13.37m100.00------6.80-20.01-20.011.66-8.650.1553--6.09---176.99-87.95-15,455.17-127.653.1515.42-1,139.66-794.78---20.25----31.113.0212.38--40.20--
Evaxion Biotech A/S - ADR3.30m-11.46m13.49m49.00------4.10-16.80-16.800.8311--------67,244.90---100.11---131.65-----347.86-131,560.30------------4.51--65.53--
Pharmacyte Biotech Inc0.004.50m13.52m2.003.480.28473.01--0.50580.50580.006.870.00----0.0035.90-7.4238.19-7.68------------0.00-------299.38------
Sensei Biotherapeutics Inc0.00-29.67m13.58m28.00--0.26-----1.18-1.180.002.080.00----0.00-39.73-47.03-42.67-54.33------------0.0232------29.82--42.16--
Hcw Biologics Inc3.92m-38.37m13.63m45.00------3.47-1.04-1.040.1068-0.16660.1183--5.7687,170.22-115.73---199.07--31.17---978.10-----146.502.75---57.72---67.74------
NRX Pharmaceuticals Inc0.00-24.83m13.65m2.00---------1.62-1.620.00-1.700.00-------197.97-120.57---168.40-----------189.12--------24.14------
Aspira Women's Health Inc8.92m-15.95m13.80m64.00------1.55-1.45-1.450.801-0.28921.5315.115.79139,421.90-273.16-110.58-3,758.30-151.8857.8445.23-178.80-334.080.5542-17,354.00----11.8524.5644.15---26.65--
Cingulate Inc0.00-19.10m14.52m13.00--1.14-----141.60-141.600.003.950.00----0.00-368.85-----------------47.380.0042-------33.14------
Inhibitor Therapeutics Inc0.00-3.02m14.65m3.00--3.54-----0.0175-0.01750.000.0240.00----0.00-34.8327.48-34.9932.70------------0.000.00-----125.39------
AIM ImmunoTech Inc201.00k-28.05m14.72m26.00--2.16--73.21-0.5703-0.57030.0040.10680.0082--12.187,730.77-113.70-45.64-149.16-48.3571.14-231.75-13,952.74-11,695.01----0.3018--43.26-11.26-48.94--35.73--
Data as of Nov 12 2024. Currency figures normalised to NRX Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

4.69%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 2024240.32k2.24%
AdvisorShares Investments LLCas of 30 Jun 2024108.09k1.01%
Geode Capital Management LLCas of 30 Jun 202465.66k0.61%
BlackRock Fund Advisorsas of 30 Jun 202429.08k0.27%
Virtu Americas LLCas of 30 Jun 202417.04k0.16%
SSgA Funds Management, Inc.as of 30 Jun 202416.72k0.16%
One Wealth Management Investment & Advisory Services LLCas of 30 Sep 202415.04k0.14%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 20244.40k0.04%
RBC Capital Markets LLC (Investment Management)as of 30 Jun 20244.00k0.04%
Tower Research Capital LLCas of 30 Jun 20243.33k0.03%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.